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EMAP-II Expression Is Associated with Macrophage
Accumulation in Primary Uveal Melanoma
Ruud Clarijs, Lia Schalkwijk, Dirk J. Ruiter, and Robert M. W. de Waal
PURPOSE. Primary uveal melanoma may contain arcs, loops, and
networks of periodic acid-Schiff (PAS)–positive patterns, along
which numerous macrophages are present. Their recruitment
into tumor tissue is mediated by chemotactic cytokines, for
which vascular endothelial growth factor (VEGF)-C and endo-
thelial monocyte–activating polypeptide ((EMAP)-II are candi-
dates. In this study, the extent of VEGF-C and EMAP-II immu-
noreaction was related to infiltration of macrophages.
METHODS. Serial sections of 25 primary uveal melanoma lesions
were analyzed by immunohistochemistry.
RESULTS. The analysis showed no correlation of VEGF-C immu-
noreaction and localization of macrophages. However, accu-
mulation of macrophages occurred at sites of EMAP-II expres-
sion, especially in areas containing nests of tumor cells,
surrounded by arcs, loops, and network patterns. In tumors
with a strong EMAP-II immunoreaction, the adhesion molecule
intracellular adhesion molecule (ICAM)-1 was strongly ex-
pressed on endothelial cells. EMAP-II–positive endothelial cells
did not express VEGF receptor-2. However, extensive release
of von Willebrand factor was observed. Signs of apoptosis were
found neither in tumor cells nor endothelial cells.
CONCLUSIONS. In uveal melanoma, macrophages accumulate at
sites of EMAP-II expression. Based on the results, it may be
hypothesized that this process of chemotaxis is facilitated by
EMAP-II–dependent expression of ICAM-1 on vascular endo-
thelial cells and concomitantly leads to localized vascular dam-
age, as indicated by release of von Willebrand factor. (Invest
Ophthalmol Vis Sci. 2003;44:1801–1806) DOI:10.1167/
iovs.02-0624
In both primary uveal and cutaneous melanoma, nine differ-ent patterns of extracellular matrix deposition have been
identified by conventional periodic acid-Schiff (PAS) stain-
ing.1–3 These different patterns appear to be of prognostic
significance. Especially, the presence of PAS-positive arcs,
loops, and network patterns has been associated with poor
survival.1–4
In a recent study,5 we suggested that these fibrovascular
septa constitute a fluid-conducting meshwork and contain en-
dothelial cells, stromal cells, and macrophages along the arcs,
loops, and network patterns. Other reports6,7 also have noted
the abundant presence of macrophages in uveal melanoma.
Despite this abundance,5–7 their role in uveal melanoma is
largely unknown. Macrophages may be involved in angiogen-
esis (reviewed in Ref. 8), which is supported by a recent study
that showed that the number of macrophages was related to
microvascular density.6 High numbers of macrophages located
in the tumor have also been related to poor prognosis in
primary uveal melanoma6,7 and in other tumor types.9–11 Fur-
thermore, their strict colocalization with the arcs, loops, and
network patterns5,6 suggests either a role in the development
of these patterns or, alternatively, the use of these patterns to
invade the tumor lesion. It is unknown how invasion of mac-
rophages in uveal melanoma is mediated. As recently reported,
in xenografted melanoma, macrophages were recruited by
vascular endothelial growth factor (VEGF)-C,12 which is also
expressed in uveal melanoma.13
Besides VEGF-C, endothelial monocyte–activating polypep-
tide (EMAP)-II may also be involved in the process of macro-
phage invasion because of its ability to attract monocytes and
granulocytes.14,15 EMAP-II mRNA has been detected in normal
tissue and in tumors.16–21 It was originally described as a
tumor-derived cytokine, isolated from the MethA tumor super-
natant.14,15 It is involved in embryonic development,16,22,23
inflammation,21,24 and autoimmune disease.25 The possible
effects of EMAP-II on tumor growth are complex.26 On the one
hand, release of EMAP-II by hypoxic or apoptotic tumor cells
may be involved in macrophage influx and subsequent mac-
rophage-mediated angiogenesis in hypoxic or apoptotic ar-
eas.14,15,17 Indeed, hypoxic prostate adenocarcinoma cells re-
lease EMAP-II.20 Infiltration of blood-stream monocytes in
tumor tissue is mediated by endothelial adhesion proteins
ICAM-1 and VCAM-1 and, to a lesser extent, P- and E-selectin
(for extensive review, see Ref. 27). If EMAP-II expression me-
diates recruitment of monocytes and resident macrophages to
malignant tumors, this would require concomitant expression
of endothelial adhesion proteins. It was already described pre-
viously that P- and E-selectin are upregulated on endothelial
cells under the influence of recombinant EMAP-II in vitro.14 On
the other hand, EMAP-II–mediated influx of macrophages may
enhance the immune response against a tumor and thereby
counteract tumor growth. Furthermore, EMAP-II may also in-
hibit tumor growth by targeting the tumor vascular bed
through induction of endothelial cell apoptosis,18 by binding
to -adenosine triphosphate (ATP) synthase28 and priming the
tumor vasculature for (local) destruction by TNF-.19,29,30 Ev-
idence of these previously proposed mechanisms is circum-
stantial, however, and therefore speculative. Most data in re-
cent literature were obtained by studying the effects of
applied, recombinant EMAP-II. Thus, the effects of endogenous
EMAP-II produced in the tumor interstitium are unclear.
To elucidate the role of endogenous, tumor-derived EMAP-II
in primary uveal melanoma, we evaluated both the occurrence
and localization of EMAP-II, ICAM-1, and VCAM-1 and deter-
mined the presence of macrophages by immunohistochemis-
try. In addition, levels of apoptosis, endothelial activation (as
indicated by expression of VEGF receptor (VEGFR)-231 and
signs of endothelial damage (as characterized by the release of
von Willebrand Factor [vWF]32) were studied. Finally, we in-
vestigated VEGF-C expression in relation to the presence and
localization of macrophages.
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MATERIALS AND METHODS
Tissues
Tissues were obtained according to guidelines of the Dutch legislation,
and our work adhered to the tenets of the Declaration of Helsinki.
Frozen specimens from 25 uveal melanomas were obtained from the
disease archives of the University Medical Centre Nijmegen where they
were stored at 130°C. Presence of disease in all specimens had been
determined by a pathologist. All primary melanomas were obtained by
surgery, and data of the clinical outcome were obtained for 16 patients
with a follow-up time from 1 to 13 years (median 4.5 years). The uveal
melanomas varied from 7 to 28 mm in diameter (median, 22 mm) and
included 23 choroidal and 2 ciliary melanoma lesions. Uveal melanoma
lesions were divided in two parts along the maximal diameter. One
part was formalin fixed and the other part was snap frozen. Hematox-
ylin and eosin (H&E) staining was used on paraffin-embedded sections,
and the 25 uveal melanomas were classified as 5 spindle cell type and
20 epithelioid or mixed type. Azan and PAS histochemistry without
counterstaining on unbleached paraffin-embedded sections showed
that 10 (44%) uveal melanomas contained loops and networks matrix
patterns (Fig. 1A).1,2,5,13,33 It appeared that in lesions previously clas-
sified as arcs, loops, and network patterns,1,2 the presence of arcs
(with and without branching) was minimal. In addition, the arcs,
loops, and network patterns were focally present in a tumor. There-
fore, it is possible that sampling errors occurred, leading to evaluation
of a section containing no network patterns, whereas they were
present in other parts of the tumor. Taken together, these consider-
ations may explain the relatively low incidence of arcs, loops, and
network patterns in our specimens. In our experience,5,13 the extent
of melanin pigmentation did not significantly hamper the detection of
extracellular matrix by PAS and Azan histochemistry. The use of PAS
and Azan histochemistry in identifying matrix patterns was recently
confirmed by immunofluorescence and electron microscopy.5
Antibodies
Antibodies used for immunohistochemistry are listed in Table 1. Anti-
CD34 (QBEnd/10), anti-CD68 (Kp1 and PG-M1), and anti-vWF were
from Dako (Glostrup, Denmark). Anti-ICAM-1 (PN-E12.1) was raised in
our laboratory,35 and anti-VCAM-1 was from Immunotech SA (Mar-
seilles, France). Anti-VEGFR-2 (Clone KDR-2) was from Sigma (St.
Louis, MO). Goat polyclonal antibodies to VEGF-C were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit polyclonal
antibodies EMAP-II (SA 2846) were obtained from Matthias Clauss (Max
Planck Institute, Bad Nauheim, Germany). The rabbit was boosted
once against a purified recombinant peptide containing 20 amino acids
located at the amino terminal site of the mature human EMAP-II form.
Control experiments demonstrated the specificity of the antibodies to
both mouse and human EMAP-II and its precursor p43, as previously
shown.17,34
Immunohistochemistry
Four-micrometer cryosections were air dried and fixed in acetone at
room temperature for 10 minutes. Only strongly pigmented sections
were bleached by incubating the sections in 3.0% (vol/vol) hydrogen
peroxide and 1.0% (wt/vol) disodium hydrogen phosphate for 18
hours at room temperature. Cryosections were incubated with 3%
hydrogen peroxide for 30 minutes and subsequently with 20% normal
goat (EMAP-II and vWF staining) or horse serum (other staining) for 10
minutes. Successive sections of each specimen were incubated with
QBEnd/10 (diluted 1:100), anti-EMAP-II (diluted 1:80) polyclonal anti-
bodies, Kp1 (diluted 1:100), PG-M1 (diluted 1:50), PN-E12.1 (undiluted
supernatant), anti-VCAM-1 (diluted 1:40), anti-vWF (diluted 1:300), or
anti-VEGF-C (diluted 1:20) for 60 minutes at room temperature. Anti-
VEGFR-2 (diluted 1:400) was incubated overnight at 4°C. After the first
and all following incubation steps, sections were rinsed with ample
phosphate-buffered saline (PBS). Then secondary, 1:200 diluted biotin-
ylated affinity-purified anti-rabbit IgG (for the EMAP-II and vWF stain-
FIGURE 1. PAS-histochemistry (A) and immunohistochemical analysis
of CD34 (B) and EMAP-II (C, D) expression and presence of macro-
phages (i.e., CD68-positive cells) (E, F) KP1, (G) MG-P1, and laminin
(H) in (serial) sections of primary uveal melanoma. PAS histochemistry
without bleaching decorates loops and network patterns containing
melanophages (A, arrowhead). The vasculature was identified by an
anti-CD34 mAb (B). Often the endothelial lining appeared to be dis-
continuous (arrowhead) and damaged (arrow). In areas with stron-
gest EMAP-II immunoreaction (C), abundant CD68 staining was
present, associated with the vasculature (CD34 staining of the boxed
area is depicted in B), indicating the accumulation of macrophages (E).
(C, E, ✽) Corresponding areas. EMAP-II positivity of tumor cells in an
area without accumulation of macrophages can be explained by the
detection of its precursor p43 which is retained intracellularly.17,34
EMAP-II positivity of tumor cells in an area without accumulation of
macrophages is explained by the detection of the EMAP-II 34,000 form,
which is retained intracellularly.17,34 Inflammatory infiltrating cells
(other than macrophages) are negative for EMAP-II (C, ✽✽). Especially
in melanoma-containing loops and network patterns (D, arrow),
EMAP-II immunoreaction was high. Next to macrophages (F, arrow),
tumor cells were occasionally positive for CD68, stained by the KP1
mAb (F, ✽). In a serial section, macrophages stained for CD68 by
MP-G1 mAb (G) showed that they are closely related to the extracel-
lular matrix structures containing laminin (G, H). Use of CD68 mAb
Kp1 and MG-P1 confirmed earlier data of Ma¨kitie et al.6 (B–H) Coun-
terstained with Harris’ hematoxylin. Magnification (A, B, D, F) 100;
(C, E) 40; (G, H) 400.
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ing), anti-goat (for VEGF-C staining), or anti-mouse IgG (all other
staining) (Vectastain; Vector Laboratories, Burlingame, CA) was incu-
bated for 30 minutes, followed by a 30-minute (VEGFR-2 and VEGF-C
staining) or 45-minute (all other staining) incubation with peroxidase-
labeled avidin-biotin complex (ABC, Vectastain; Vector Laboratories).
Subsequently, the sections stained with VEGFR-2 and VEGF-C antibod-
ies were incubated for 10 minutes with biotinylated tyramine (dilution
1:200), followed by a 20-minute incubation with ABC-peroxidase so-
lution (catalyzed reporter deposition method36). All staining was de-
veloped by a 10-minute incubation with a 0.4 mg/mL 3-amino-9-ethyl-
carbazole solution (Aldrich, Steinheim, Germany).
Four-micrometer paraffin-embedded serial sections were deparaf-
finized in xylene and rehydrated in an ethanol series. Antigen retrieval
was performed by boiling sections for 10 minutes in sodium citrate
buffer (pH 6.0) using a microwave oven. Endogenous peroxidase
activity was blocked by treating the sections for 30 minutes with PBS
containing 3% hydrogen peroxide. Then, sections were incubated with
20% normal horse serum (Vector Laboratories) for 10 minutes. Of each
specimen, the sections directly adjacent to the section stained by Azan
histochemistry were incubated with QBEnd/10 mAb (diluted 1:50) and
further processed as described earlier.
In control sections, primary antibodies were omitted. All staining
was counterstained for 45 seconds with Harris’ hematoxylin (Merck,
Darmstadt, Germany) at room temperature and were mounted (Imsol;
Klinipath BV, Duiven, The Netherlands).
Determination of Macrophage Density
In a subset of tumors expressing EMAP-II, the density of macrophages
in areas with low or without immunoreaction and in areas with strong
immunoreaction was assessed by visual examination of EMAP-II and
CD68 immunostaining, using an ocular with counting grid at 163
magnification. In a tumor containing areas with both low and strong
EMAP-II immunoreaction, numbers of macrophages were counted in
10 nonoverlapping fields for either level of immunoreaction. Statistical
analysis was performed by a paired t-test.
Detection of Apoptosis
Apoptotic cells were detected in 4-m cryosections with a cell viability
test (ApopTag Kit S7100; Introgen Therapeutics, Houston, TX), accord-
ing to the manufacturer’s guidelines.
RESULTS
Vascular Staining
In all 25 uveal melanomas, the vasculature was identified by
anti-CD34 mAb staining on frozen sections (Table 1) and mor-
phologic properties, as described previously.5,13,37 Often, the
endothelial layer was discontinuous, compatible with endothe-
lial damage (Fig. 1B). Although blood vessel density varied
among different lesions, no evident increase of blood vessel
density in distinct areas within a tumor lesion was observed.
Azan and PAS histochemistry (Fig. 1A) and CD34-immunohis-
tochemistry of serial paraffin-embedded sections indicated that
the blood vasculature was closely associated with loops and
network patterns, as described previously.5
Colocalization of EMAP-II Expression
and Macrophages
EMAP-II expression was detected in 23 (92%) of 25 uveal
melanomas as a cytoplasmic staining of tumor cells (Figs. 1C,
1D). In 15 tumors, EMAP-II expression was localized in circum-
script areas. Especially, tumor cells directly surrounding blood
vessels were strongly positive for EMAP-II. In eight melanomas,
all tumor cells were intensely positive for EMAP-II (referred to
as ubiquitous immunoreaction). By comparison to parallel en-
dothelial CD34 staining in serial sections, EMAP-II was also
present on blood vascular endothelium in three tumors in the
areas with local expression of EMAP-II, whereas in six tumors
with ubiquitous EMAP-II staining of tumor cells, endothelial
cells were also ubiquitously positive. Especially in areas of
loops and network patterns, all tumor cells showed strong
EMAP-II immunoreaction (Fig. 1D). Strong endothelial EMAP-II
immunoreaction was also observed in areas with necrosis (not
shown). Finally, background staining patterns that could inter-
fere with EMAP-II expression analysis were not observed when
using other polyclonal antibodies (e.g., anti-vWF polyclonal
antibodies).
In all 25 melanomas, macrophages could be detected by
CD68 staining and by morphologic characteristics (compare
serial sections in Figs. 1E, 1F). When using Kp1 antibody,
tumor cells were also weakly positive for CD68 in eight mela-
noma lesions (Fig. 1F), whereas incubation with the PG-M1
mAb did not result in CD68 staining of melanoma cells (Fig.
1H). These data confirm earlier results.6,38 Both macrophages
and melanophages were strongly associated with the extracel-
lular loops and network patterns, which contain laminin (Figs.
1G, 1H).5
In the 15 tumors with local differences in EMAP-II staining
intensity, macrophages were consistently more abundant in
areas with higher EMAP-II levels, especially around blood ves-
sels (compare serial sections in Figs. 1C, 1E). Counting of the
number of macrophages in four of these tumors demonstrated
a significant difference (P  0.0001) between those in tumor
areas with negative to low EMAP-II immunoreaction (72  49
macrophages/mm2; mean SD) and those in areas with strong
EMAP-II immunoreaction (457  129 macrophages/mm2).
Macrophages were detected around both EMAP-II–negative
(n  12) and –positive (n  3) blood vessel endothelium. In
eight melanomas with ubiquitous EMAP-II immunoreaction,
macrophages were equally distributed over the tumor tissue. In
these tumors, macrophages were present around EMAP-II–
negative and –positive (n  7) vessels as well. In areas con-
taining loops and network extracellular matrix patterns, nests
of tumor cells were intensively positive for EMAP-II immuno-
staining. In addition, EMAP-II immunoreaction was lower in
areas containing no loops and network patterns compared
with areas with these patterns within one lesion.
ICAM-1 and VCAM-1 Immunostaining
Coexpression of ICAM-1 and EMAP-II was found on tumor cells
in all 23 EMAP-II–positive cases (Figs. 2A, 2B). Conversely, in
areas with no or low tumoral EMAP-II immunoreaction, ICAM-1
was not detected on tumor cells. In only 3 of 15 tumors with
local EMAP-II expression was ICAM-1 expression observed on
EMAP-II–positive endothelium, whereas this was the case in 6
of 8 tumors (Figs. 2A, 2B) with generalized immunoreaction.
ICAM-1 was often expressed on a subset of endothelial cells
TABLE 1. Primary Antibodies Used: Antigens and Type of
Cells Stained
Antigen Antibody Type of Cell
CD34 QBEnd/10 Endothelial
EMAP-II Anti-EMAP-II* Tumor, endothelial
CD68 Kp1 Macrophages
CD68 PG-M1 Macrophages
VEGF-C Anti-VEGF-C* Macrophages
ICAM-1 PN-E12.1 Endothelial
VCAM anti-VCAM-1 Endothelial
vWF anti-vWF* Endothelial
VEGFR-2 anti-VEGFR-2 Endothelial
* Polyclonal antibody.
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(Figs. 2C, 2D). In this group of tumors, EMAP-II–negative en-
dothelium did not express ICAM-1 (central vessel in Figs. 2A,
2B).
In only four melanomas, delicate VCAM-1 staining was de-
tected on both EMAP-II–positive and –negative blood vascular
endothelium (not shown). VCAM-1 expression was never ob-
served on tumor cells.
VEGFR-2 and vWF Immunostaining
We analyzed 16 EMAP-II–positive uveal melanomas for the
presence of VEGFR-2 and vWF as markers of endothelial acti-
vation and damage, respectively. In 14 melanomas, comparison
to parallel EMAP-II staining demonstrated that EMAP-II–positive
endothelial cells showed no expression of VEGFR-2 (Figs. 3A,
3B). However, strong staining of vWF in endothelial cells and
underlying tissue indicated a release of vWF by this endothe-
lium (Figs. 3A, 3C). Conversely, EMAP-II–negative endothelial
cells expressed VEGFR-2 in five melanomas (Figs. 3D, 3E)
whereas no evident damage was detected in these cells by vWF
staining (not shown). In only two tumors, a weak colocaliza-
tion of EMAP-II positivity, VEGFR-2, and absence of vWF-re-
lease was observed. Patterns similar to those of EMAP-II stain-
ing were not observed when using other polyclonal antibodies
(e.g., anti-vWF polyclonal antibodies).
Detection of Apoptosis
Apoptosis was detectable in only 3 of 15 uveal melanomas. In
none of the tumors were apoptotic endothelial cells found. In
one tumor, an evidently necrotic area positive for EMAP-II,
showed staining, whereas in the remaining tumor cells, apo-
ptosis was absent. In the other two tumors, apoptosis was
confined to a few tumor cells dispersed over the entire tumor
area (not shown).
Absence of Colocalization of VEGF-C Expression
and Macrophages
Finally, we analyzed 12 melanomas for expression of VEGF-C.
In six melanomas, VEGF-C was expressed in restricted areas.
No evident colocalization of accumulation or absence of mac-
rophages and VEGF-C expression was observed in any lesion
(data not shown).
Correlation with Clinical Outcome
In only one patient, liver metastasis was found 2 years after
enucleation. This tumor contained PAS-positive loops and net-
work patterns and ubiquitous EMAP-II immunoreaction of tu-
mor and endothelial cells and macrophages was equally dis-
tributed over the lesion. In addition, ICAM-1 was expressed by
the tumor and a subset of endothelial cells. No VCAM-1 ex-
pression or apoptosis was observed. EMAP-II–positive endothe-
lial cells lacked expression of VEGFR-2 but stained strongly for
vWF. VEGF-C expression was not evaluated.
DISCUSSION
Recently, we described that the arcs, loops, and network
extracellular matrix patterns may represent a fluid-conducting
meshwork in xenografted and primary uveal melanoma.5 Our
findings indicated that these structures closely parallel the
previously described vascular channels.39 Although it has been
demonstrated that melanoma cells may express nonmelano-
cytic markers like endothelial-cell–associated CD34 and mac-
rophage-associated CD68,39,40 we could not confirm the pres-
ence of blood-conducting channels lined by tumor cells.
Instead, septa consisting of extracellular matrix components
that could be visualized by PAS and Azan histochemistry sur-
rounded tumor cell nests. Remarkably, many macrophages
(i.e., CD68-positive cells) were found associated with this
meshwork in melanoma xenografts. We now have studied the
presence and localization of macrophages in uveal melanoma,
focusing on the mechanisms underlying infiltration by this cell
FIGURE 3. Immunohistochemical analysis in serial sections of EMAP-II
(A, D), VEGFR-2 (B, E), and vWF (C) expression in primary uveal
melanoma. Although endothelial EMAP-II immunoreaction was slight
(A), VEGFR-2 were not expressed (B), whereas endothelial damage
was shown by leakage of vWF toward surrounding tumor tissue (C,
arrows). In the absence of endothelial EMAP-II expression (D),
VEGFR-2 is expressed (E). All stains were counterstained with Harris’
hematoxylin. Magnification, 250.
FIGURE 2. Immunohistochemical analysis in serial sections of EMAP-II
(A) and ICAM-1 (B) expression in primary uveal melanoma. Intense
ubiquitous EMAP-II staining and ICAM-1 expression were observed in
both tumor and endothelial cells (A, B). Boxed areas in (B) are shown
enlarged in (C) and (D). Part of the EMAP-II–positive endothelial cells
express ICAM-1 (C, D, arrow) whereas the central EMAP-II–negative
vessel expressed no ICAM-1 (A, B). All stains were counterstained with
Harris’ hematoxylin. Magnification: (A, B) 100; (C, D) 250.
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type. Our results also show that in uveal melanoma, macro-
phages are abundantly present and colocalize with the extra-
cellular matrix patterns containing laminin.5,41
In uveal melanoma containing loops and network extracel-
lular matrix PAS-positive patterns, the monocyte chemoattrac-
tant protein EMAP-II was abundantly present in the cytoplasm
of tumor cells and was accompanied by local macrophage
accumulation. Additional analysis of uveal melanomas lacking
these patterns showed that different levels of local EMAP-II
staining within one tumor were present and that macrophages
were preferentially located in areas with highest EMAP-II im-
munoreaction. These data support the hypothesis that tumor
cells recruit local resident tissue macrophages and peripheral
monocytes by release of EMAP-II. This hypothesis was corrob-
orated by several previous studies on the expression of EMAP-II
in tumor cells and the ability of EMAP-II to attract macro-
phages.14,15 Indeed, infiltration of the tumor may be facilitated
by the loops and network patterns by their serving as a gate-
way. However, secondary changes including extensive retinal
detachments, glaucoma, rubeosis, and intraocular hemorrhage
may contribute to the influx of macrophages as well, because
most of the lesions analyzed were large. Because VEGF-C ex-
pression did not colocalize with absence or accumulation of
macrophages, our data suggest that VEGF-C does not play a
substantial role in macrophage invasion in uveal melanoma.
EMAP-II is normally retained intracellularly and can be re-
leased and partially processed by several triggers, including
apoptosis and hypoxia.17,20 Because apoptotic cells were
hardly present in the tumor lesions, this does not seem to be a
decisive factor in EMAP-II expression in uveal melanoma. Hy-
poxic tumor cells may express hypoxia inducible factor (HIF)-
18,42 and release vascular endothelial growth factor (VEGF)-A.
In this respect, it is noteworthy that we observed no release of
VEGF-A in these primary uveal melanoma lesions.13 However,
to the best of our knowledge, expression of HIF-1 in uveal
melanoma has not been reported thus far.
Purified recombinant mature EMAP-II protein activates en-
dothelial cells and enhances the expression of adhesion mole-
cules P- and E-selectin.14 These adhesion molecules mediate
invasion of different types of leukocytes into the underlying
tissue (for review, see Ref. 27). Macrophage infiltration is
primarily mediated by ICAM-1 and VCAM-1 adhesion mole-
cules, however. Remarkably, one of our first observations was
that EMAP-II and ICAM-1 are coexpressed on tumor cells. This
indicates that either both these molecules are upregulated by
the same stimulus, or that EMAP-II expression induces ICAM-1
expression by an autocrine mechanism. Moreover, ICAM-1 was
predominantly expressed on the vascular endothelium in those
tumors that showed intense ubiquitous staining for EMAP-II. In
tumors with focal EMAP-II immunoreaction, the endothelium
was often negative for both EMAP-II and ICAM-1, suggesting
that a certain threshold level of EMAP-II binding to endothelial
cells is necessary for induction of ICAM-1. Functional experi-
ments in cell cultures are necessary to confirm these findings.
Because only four tumors expressed vascular cell adhesion
molecule (VCAM) on their vessels, it is unlikely that this adhe-
sion molecule is induced by EMAP-II expression and contrib-
utes to infiltration of monocytes.27
To elucidate further the role of endogenously produced
EMAP-II in primary uveal melanoma, we evaluated additional
parameters that have been associated with EMAP-II expression
in the literature—that is, the induction of apoptosis and of
angiogenesis. As stated earlier, EMAP-II is involved in macro-
phage influx in several types of carcinomas. This has been
related to tumor progression9,10 and may be explained partly
by macrophage-induced neovascularization43 (for review see
Ref. 44). We hypothesized that in primary uveal melanoma,
hypoxic tumor cells secrete EMAP-II, contributing to recruit-
ment and infiltration of monocytes into the tumor tissue. Our
results suggest that this sequence of events is not followed by
angiogenesis: EMAP-II–positive endothelium did not express
VEGFR-2 as a sign of endothelial activation, as occurs during
angiogenesis. Rather, our data suggest extensive release or
leakage of vWF out of the EMAP-II–positive endothelial cells
into surrounding tumor tissue, indicating endothelial cell dam-
age. These findings imply that EMAP-II, instead of triggering
angiogenesis, rather induces endothelial cell death in vivo. In
uveal melanoma therefore, EMAP-II appears to have an adverse
effect on the neovasculature, supporting the results obtained
by administering exogenous EMAP-II in previous stud-
ies.14,18,45 It has been demonstrated that EMAP-II induces en-
dothelial apoptosis18 after release by apoptotic (tumor) cells.
However, in our study, no evident apoptosis of EMAP-II–posi-
tive endothelial or tumor cells was observed. The involvement
of apoptosis, either as a trigger of EMAP-II induction or as a
result of its formation, remains therefore questionable, at least
in uveal melanoma. Our data support earlier results indicating
that processing and release of EMAP-II is not restricted to
apoptotic cells but may also occur in cells that ultimately die by
ischemia and subsequent necrosis.
The question arises whether local administration of EMAP-II
will induce extensive vascular damage that may lead to necro-
sis of the tumor. Previous data from our laboratory indicate that
the PAS-positive loops and network patterns may be involved
in tumor cell nutrition (Clarijs R, van Dijk M, van Kraats A,
Ruiter DJ, de Waal RMW, manuscript submitted). Thus, by
inhibition of angiogenesis through administration of EMAP-II,
uveal melanoma may (partly) escape this intervention by for-
mation of loops and network patterns. Local administration of
EMAP-II may also lead to extensive influx of macrophages,
which may trigger an immune response or, alternatively, result
in release of growth factors necessary for tumor growth and
subsequent metastasis. Thus, the effects of EMAP-II are com-
plex, and the possible effects of intervention with expression
of EMAP-II in uveal melanoma or other tumor types are yet
unpredictable and therefore require extensive additional re-
search.
Data on the clinical outcome of 16 of the patients were
obtained, with only 1 patient found to have metastatic disease.
This could be explained by the relatively short follow-up in the
patients with primary uveal melanoma, because this tumor is
notorious for metastasis after several years. Therefore, our
study did not allow us to draw any conclusion on the role of
EMAP-II expression in determining prognosis.
In summary, our data are in line with the following se-
quence of events: Tumor cells promote adhesion and invasion
of macrophages through the release of EMAP-II. This process is
mediated by EMAP-II–induced expression of ICAM-1 on endo-
thelial cells. Infiltrating macrophages follow the PAS-positive
extracellular matrix patterns. Binding of substantial amounts of
EMAP-II to vascular endothelial cells may lead to endothelial
damage, resulting in vWF release.
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